DiaGyn

Targeted Chemotherapy for Breast and Ovarian Cancer

Health Tech & Life Sciences
Non Active, Dec 2022 ceased to operate

Company Overview

Snapshot

Founded in September 2015, DiaGyn operates with 1–10 employees. The company ceased operations in December 2022, having focused on developing targeted chemotherapy solutions.

Business overview

DiaGyn specializes in developing solutions for women's health, integrating drug development and molecular genomics with personalized therapeutic approaches. The company's core technology addresses BRCA1/2 mutations in ovarian and breast cancer through a treatment strategy utilizing nanoparticle technology. Its product, DIG790, is designed for advanced epithelial ovarian cancer (EOC) and comprises mesoporous silica nanoparticles loaded with docetaxel, capped with cyclodextrin for targeted drug release. DiaGyn operates within the Health Tech & Life Sciences sector, specifically focusing on drug discovery and development.

Company Intelligence Q&A

What is DiaGyn's primary focus?
DiaGyn focuses on developing targeted chemotherapy solutions for breast and ovarian cancer, particularly addressing BRCA1/2 mutations, using nanoparticle technology.
What is DIG790?
DIG790 is DiaGyn's innovative product for treating advanced epithelial ovarian cancer (EOC). It consists of mesoporous silica nanoparticles loaded with docetaxel, designed for targeted drug release within malignant cells.
When was DiaGyn founded?
DiaGyn was founded in September 2015.
What is the status of DiaGyn?
DiaGyn is currently non-active, having ceased operations in December 2022.
Who is a co-founder of DiaGyn?
Roy Farfara is a co-founder of DiaGyn.

External links